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Abstract 
 
Venous thrombosis occurs when pathological clotting arises in the venous circulation. 
Factor XIII (FXIII) crosslinks fibrin, increasing the mechanical stability of clots. FXIII binds to 
fibrinogen, which accelerates enzymatic activation of FXIII. Recent work implicated FXIII-
fibrinogen binding as a determinant of thrombus size. Murine studies suggest that fibrinogen γ-
chain residues 390-396, which are highly conserved in human fibrinogen, mediate this binding. 
We hypothesized that mutating human γ-chain residues 390-396 would disrupt FXIII-fibrinogen 
binding. We expressed the native γ-module (residues γ148-411, γ-modNat) and a γ-module with 
residues 390-396 mutated to alanines (γ-mod390-396A). γ-mod390-396A exhibited decreased affinity 
for FXIII relative to γ-modNat in an enzyme-linked immunosorbent assay, suggesting that γ-chain 
residues 390-396 mediate FXIII-fibrinogen binding in humans. Future studies will use γ-modNat 
as “bait” to probe FXIII for the residues involved in fibrinogen binding. Identification of the 
binding residues on FXIII may yield a potential target for reducing venous thrombosis. 
 
 
Introduction 
As many as 1,000,000 cases of venous thrombosis and pulmonary embolism, collectively 
termed venous thromboembolism, arise every year in the United States with a mortality rate of 
30% within 30 days of incidence.1 Venous thrombosis occurs when pathologic clotting arises in 
venous circulation.2 These intravenous clots, termed venous thrombi, are mainly composed of 
red blood cells and fibrin.2 Coagulation is activated in vein valve pockets, leading to thrombin-
mediated conversion of soluble plasma fibrinogen into insoluble fibrin. Fibrin then polymerizes, 
forming the framework of the clot. Venous thrombi can detach from the endothelium and 
occlude lung vasculature in a process called pulmonary embolism. 
Recently, the Wolberg laboratory determined that FXIII activity contributes to venous 
thrombosis.3 FXIII is a protransglutaminase that circulates as a tetramer composed of two 
catalytic A subunits and two inhibitory B subunits (FXIII-A2B2). FXIII is activated during 
coagulation when thrombin, a serine protease, cleaves an activation peptide from the FXIII-A 
subunits.4,5 This reaction is followed by calcium-mediated dissociation of the regulatory FXIII-B 
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subunits.6 Activated FXIII covalently crosslinks fibrin, strengthening the clot and rendering it 
more resistant to lysis.7 FXIII crosslinking of fibrin also promotes red blood cell retention in 
venous thrombi and consequently, determines venous thrombus size.3,8 
FXIII and fibrinogen circulate as a tightly-bound complex (KD ~10 nM
9), and fibrinogen 
delivers bound FXIII to nascent clots. The majority of FXIII in plasma is bound to fibrinogen.10 
FXIII-fibrinogen binding accelerates FXIII activation by promoting FXIII-B dissociation and 
thrombin-mediated cleavage of FXIII-A activation peptide.11 However, the residues that mediate 
FXIII-fibrinogen binding are currently unknown. Aleman et al. found that mice with residues 
390-396 on the γ-chain of fibrinogen mutated to alanines (Fibγ390-396A) showed delayed FXIII 
activation relative to wild-type. This finding suggests that fibrinogen residues 390-396 facilitate 
FXIII binding in blood.3 Consistent with this observation, Fibγ390-396A fibrinogen displays 6-fold 
reduced binding affinity for FXIII compared to wild-type fibrinogen and a corresponding 5-fold 
decrease in FXIII activation rate.3 In venous thrombosis models, Fibγ390-396A mice produce 
smaller thrombi with reduced red blood cell content, similar to FXIII-A-deficient mice.3 
Interestingly, Fibγ390-396A mice do not exhibit a bleeding phenotype. Collectively, these findings 
suggest that the FXIII-fibrinogen interaction is a potential target for reducing venous 
thromboembolism while limiting the risk for bleeding. 
The goal of my project was to define the key residues for binding on both fibrinogen and 
FXIII. Because γ-chain residues 390-396 are highly conserved between mouse and human, we 
hypothesized that these residues also mediate FXIII-fibrinogen binding in humans. My findings 
indicate that when γ-chain residues 390-396 are mutated to alanines, the γ-module of fibrinogen 
has decreased affinity for FXIII-A2B2 compared to wild-type γ-module and that FXIII-A2 and 
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FXIII-A2B2 do not crosslink the 390-396A mutant γ-module as effectively as wild-type γ-
module. 
 
Materials and Methods 
Materials and Instruments 
Full-length human fibrinogen cDNA was provided by Dr. Susan Lord (University of 
North Carolina at Chapel Hill). Taq polymerase was obtained from New England BioLabs, Inc. 
(Ipswich, MA). Forward and reverse primers for the γ-modules (fibrinogen γ-chain residues 148-
411) were purchased from Eurofins Genomics (Huntsville, AL). FastDigest® Restriction 
Enzymes (BamHI, NdeI, HindIII, NcoI) and GeneJET PCR Purification and Gel Extraction Kits 
were obtained from Thermo Scientific (Pittsburgh, PA). Polyclonal anti-human fibrinogen was 
from Dako (Carpinteria, CA). Human FXIII-A2B2, thrombin, and anti-human FXIII-A antibody 
were from Enzyme Research Laboratories (South Bend, IN). SureBlue™ TMB Microwell 
Peroxidase Substrate (1-Component) was from Kirkegaard & Perry Laboratories, Inc. 
(Gaithersburg, MD). Recombinant FXIII-A2 was a generous gift of Novo Nordisk (Bagsværd, 
Denmark). QuikChange Site-Directed Mutagenesis Kit was from Agilent Technologies (Cedar 
Creek, TX). Mutagenesis primers and anti-human FXIII-B antibody were from Sigma-Aldrich 
(St. Louis, MO). Corifact® Human FXIII concentrate was from CSL Behring (King of Prussia, 
PA). Centrifugal filters (5 kDa cut-off) were purchased from EMD Millipore (Bellerica, MD). 
FeBABE was from Dojindo Molecular Technologies, Inc. (Rockville, MD). 
Expression of γ-module in E. coli 
Expression of γ-module in E. coli was based on a method established by Medved et al.12 
Polymerase chain reaction (PCR) of γ-module DNA utilized a forward primer that contained 
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restriction enzyme sites for BamHI and NdeI directly upstream of the γ-module start codon and a 
reverse primer containing a site for HindIII following the stop codon (Figure 1). PCR was carried 
out with a Techne Progene FRROG05Y Thermocycler. γ-module DNA was isolated from the 
initial PCR product in agarose gel, which was stained with ethidium bromide (0.5 μg/mL). Next, 
the PCR product was digested with BspHI and HindIII, and pET28b vector was digested with 
with NcoI and HindIII for 2 hours at 37°C. The digested insert and vectors were ligated, and 
DH5α E. coli was transformed with the resultant plasmid. Transformed E. coli were grown on 
agar plates with kanamycin, which selects for E. coli with the pET28b vector. Following in vivo 
amplification of vectors, a colony PCR technique was performed to amplify the plasmid DNA 
and identify positive colonies. DNA from positive colonies was sequenced by Eton Biosciences 
(Durham, NC) to screen for point mutations. Positive DNA from the colony PCR was used to 
transform Rosetta™ Cells (Novagen, Darmstadt, Germany). γ-module expression was induced 
with isopropyl β-D-1-thiogalactopyranoside. After expressing protein overnight, the protein was 
isolated, re-solubilized, and re-folded in vitro because E. coli releases the γ-module in inclusion 
bodies.12 
Enzyme-Linked Immunosorbent Assay (ELISA) of FXIII and γ-module 
A high-binding 96-well microplate was coated with human FXIII-A2B2 and incubated for 
1 hour at room temperature. After incubation, the wells were washed with 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4), 150 mM NaCl (HBS) containing 1 mM 
Ca2+ (HBS plus Ca2+) and incubated with Cappel horseradish peroxidase-goat-anti-human 
fibrinogen antibody at 4°C overnight to deplete the antibody of anti-FXIII activity. Additional 
wells were coated with either 10 µg/mL FXIII or bovine serum albumin in HBS plus Ca2+ and 
incubated for 1 hour. Wells were washed with wash buffer and blocked with HBS plus Ca2+ for 
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90 minutes. After washing again, γ-module (3.2 nM - 50 µM) was added to the wells and 
incubated for 1 hour. Wells were then washed with HBS plus Ca2+, and anti-FXIII activity 
depleted antibody was added and incubated for 60 minutes. Finally, the wells were washed with 
HBS plus Ca2+, SureBlue™ substrate was added, and reactions were monitored at 600 nm on a 
SpectraMax Plus 384 Microplate Reader (Molecular Devices, Sunnyvale, CA). We measured the 
maximum rate of change in absorbance (Vmax) and correlated Vmax with FXIII-γ-module binding 
affinity. 
Crosslinking of γ-module by FXIII 
To examine the kinetics of γ-module crosslinking by FXIII-A2B2 (0.077 mg/mL, 240 nM, 
final) or recombinant FXIII-A2 (0.040 mg/mL, 240 nM, final), FXIII was incubated with γ-
module (0.4 mg/mL, final) at room temperature and FXIII activation was triggered with 
thrombin (5 nM, final) and calcium (5 mM, final). All reactions were performed in Tris-buffered 
saline (40 mM Tris base, 150 mM NaCl, 1 mM CaCl2, pH 7.4). Reactions were stopped by the 
addition of sodium dodecyl sulfate (SDS) loading dye and boiling for 5 minutes. To determine 
the rate of FXIII solution phase activation the reactions were repeated without γ-module. 
Samples were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western 
blotting, probing for fibrinogen and FXIII-A. 
Site-directed mutagenesis of γ-module and tethered cleavage 
Primers were designed to induce cysteine substitutions at residues 389, 393, and 397 of 
the γ-module, termed γ-modF389C, γ-modT393C, and γ-modG397C, respectively. Using the 
QuikChange Kit from Agilent, mutated DNA was transformed into Rosetta™ Cells. Expression 
of these constructs utilized the aforementioned γ-module expression protocol. Size exclusion 
chromatography with a Sephadex G-75 stationary phase was used to purify γ-module products 
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for use in tethered cleavage chemistry. Purified γ-modG397C was dialyzed into metal removal 
buffer (30 mM 3-(N-morpholino)propanesulfonic acid, 4 mM ethylenediaminetetraacetic acid 
(EDTA), pH 8.2) to scour metal ions from the protein for 24 hours at 4°C. FXIII-A2B2 (isolated 
from Corifact® Human FXIII concentrate by size exclusion chromatography) was concurrently 
dialyzed against cutting buffer (50 mM 3-(N-morpholino)propanesulfonic acid, 120 mM NaCl, 
0.1 mM EDTA, 10 mM MgCl2, 10% glycerol, pH 8.0) for 24 hours at 4°C. A 5 kDa cut-off 
centrifugal filter was used to buffer exchange γ-modG397C from metal removal buffer to 
conjugation buffer (30 mM 3-(N-morpholino)propanesulfonic acid, 100 mM NaCl, 1 mM 
EDTA, 5% glycerol, pH 8.2). The cleaving reagent, the iron chelate of bromoacetamidobenzyl-
EDTA (FeBABE), was suspended in conjugation buffer, and the FeBABE solution was added to 
the γ-module and incubated for 1 hour at 37°C. FeBABE-conjugated γ-module was buffer 
exchanged into cutting buffer with a new 5 kDa cut-off centrifugal filter, and this solution was 
mixed with the FXIII in cutting buffer solution for 30 minutes, followed by a 10-minute 
incubation on ice. FeBABE cleavage was triggered with the sequential addition of ascorbic acid 
(40 mM ascorbic acid, 10 mM EDTA, pH 7.0) and hydrogen peroxide (40 mM hydrogen 
peroxide, 10 mM EDTA). After 30 seconds of cleavage, reactions were quenched with an equal 
volume of sample buffer (1:1 solution of SDS sample buffer and 80% glycerol). Samples were 
boiled for 5 minutes, and cleavage products were identified with SDS-PAGE and Western 
blotting for FXIII-A and FXIII-B subunits. 
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Results 
FXIII shows reduced binding affinity for γ-mod390-396A compared to γ-modNat 
Previous findings implicate murine fibrinogen γ-chain residues 390-396 in FXIII 
binding.7 Since γ-chain residues 390-396 are highly conserved between mouse and human, we 
hypothesized that these residues also mediate FXIII-fibrinogen binding in humans. To test this 
hypothesis, we isolated human γ-module (fibrinogen γ-chain residues 148-411) constructs with 
(γ-mod390-396A) and without (γ-modNat) the 390-396A mutation and compared binding of these 
constructs to FXIII with an ELISA. We calculated dissociation constants (KD) for FXIII-γ-
module binding and found that, compared to γ-modNat, γ-mod390-396A had reduced affinity for 
FXIII-A2B2 (10.07 versus 90.08 µM, respectively, Figure 2). These data suggest human γ-chain 
residues 390-396 contribute to FXIII-fibrinogen binding. 
Solution phase-activated FXIII crosslinks γ-modNat more readily than γ-mod390-396A 
FXIII-A2B2 binding to fibrinogen accelerates enzymatic activation. Accordingly, Aleman 
et al. observed delayed FXIII-A2B2 activation and fibrin crosslinking in clots formed from 
plasma from mice expressing γ390-396A fibrinogen.3 To investigate the role of these residues in 
human FXIII activation and crosslinking, we incubated γ-modNat and γ-mod390-396A with 
thrombin, calcium, and recombinant FXIII-A2 or FXIII-A2B2. We then detected γ-module 
crosslinked species using SDS-PAGE and by Western blotting with anti-human fibrinogen 
antibody. These experiments showed that both recombinant FXIII-A2 and FXIII-A2B2 
crosslinked γ-modNat more readily than γ-mod390-396A (Figure 3A-D). 
To test whether the reduced crosslinking seen in γ-mod390-396A was due to reduced FXIII 
activation in these reactions, we re-probed blots from the crosslinking experiments for FXIII-A 
to detect FXIII activation via a band shift associated with activation peptide cleavage. Activation 
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of both FXIII-A2B2 and recombinant FXIII-A2 was identical in the γ-modNat and γ-mod390-396A 
crosslinking reactions (4A-D). Subsequent solution-phase FXIII assays without γ-module 
indicated identical FXIII activation to that observed in the crosslinking reactions for both FXIII-
A2B2 and recombinant FXIII-A2 (Figure 5A-B). The identical activation rates observed in the 
presence and absence of fibrinogen suggest FXIII activation is occurring in solution in the 
crosslinking assays as it is in the solution-phase experiments. Consequently, the effects of the 
reduced binding affinity of FXIII with γ-mod390-396A compared to γ-modNat do not manifest in this 
assay. Therefore, the decrease in crosslinking of γ-mod390-396A compared to γ-modNat may be a 
result of disrupted protein structure in the γ-mod390-396A that hinders FXIII activity. 
FeBABE Cleavage of FXIII 
FeBABE reagent cleaves peptide chains within a 12-angstrom radius and is used in 
tethered cleavage chemistry. Although we have localized binding of FXIII to fibrinogen γ-chain 
residues 390-396, the FXIII residues mediating this interaction remain unknown. To map the 
residues on FXIII that bind to fibrinogen, we conducted tethered cleavage chemistry of FXIII 
with FeBABE. By conjugating FeBABE reagent to γ-module near residues 390-396, we 
anticipated that cleavage would occur at FXIII residues located near this motif. The reactions 
with FeBABE-γ-modG397C conjugates yielded unique bands compared to control reactions 
(Figure 6A). Unique bands appeared at approximately 27, 35, 38, 45, 50, and 57 kDa when 
probing for FXIII-A, suggesting that FeBABE reagent cleaved this subunit of FXIII. Additional 
control reactions containing triggered FeBABE-FXIII conjugates produced a similar band 
pattern, indicating that FeBABE conjugation to FXIII-A subunits likely occurred during the 
initial experiment and that the cleaved fragments do not provide information about the FXIII-γ-
module binding surface (Figure 6B). 
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Discussion 
Given the importance of FXIII-fibrinogen interactions in murine thrombosis, studying 
these interactions in human proteins may reveal new targets to reduce venous thromboembolism. 
We generated human fibrinogen γ-module in its native form and with alanine mutations to the 
proposed FXIII-binding region (residues 390-396) and compared the binding affinities of the 
constructs to FXIII via ELISA. With calculated KD values of 10.07 µM and 90.08 µM 
respectively, γ-modNat and γ-mod390-396A both showed significantly decreased FXIII affinity 
compared to full-length fibrinogen (KD ~ 10 nM
5). Thus, although γ-module bound FXIII in my 
experiments, the data suggest other components of full-length fibrinogen are important for 
FXIII-fibrinogen binding or that the γ-module is not in its native conformation. Nonetheless, the 
higher affinity of γ-modNat versus γ-mod390-396A to FXIII supports my hypothesis that γ-chain 
residues 390-396 contribute to FXIII-fibrinogen interactions in humans. 
The crosslinking assays indicate that FXIII cannot crosslink γ-mod390-396A as efficiently as 
γ-modNat. The band pattern of FXIII activation peptide cleavage is identical in crosslinking 
reactions and solution-phase reactions without γ-module. Given that crosslinking reactions do 
not utilize pre-incubated FXIII and γ-module, these results suggest that FXIII was not bound to 
either γ-module when activated in the crosslinking experiments. The inefficiency of γ-mod390-
396A crosslinking relative to γ-modNat crosslinking, therefore, cannot be attributed to hindered 
FXIII activation due to deficient FXIII binding. Instead inefficient crosslinking might be the 
result of the 390-396A mutation disrupting γ-module structure in a way that impairs crosslinking. 
Given the identical cleavage patterns of FeBABE-FXIII conjugated protein in the final 
control and the experimental reactions, any cleavage of FXIII is likely due to FeBABE 
conjugation to a free cysteine on FXIII-A2B2 and not because of module-conjugated FeBABE 
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mediating cleavage at the binding site. Excess FeBABE likely remained in the γ-module solution 
after conjugation and mixed with FXIII, subsequently conjugating to FXIII cysteine residues 
during the FXIII-γ-modG397C incubation. These results indicate that the cleavage products of the 
reaction do not represent the fibrinogen binding residues of FXIII. Further experiments will more 
stringently buffer exchange free non-γ-module-conjugated FeBABE reagent out of the reaction. 
In future studies, we will reassess my approach to use FeBABE to identify the FXIII 
residues that bind fibrinogen. The γ-module has proven problematic to work with in that it is 
difficult to purify and has a much lower affinity for FXIII than the full-length protein. We are 
exploring the use of a yeast expression system that could dramatically increase γ-module yields 
and purity.13 Alternatively, we will conduct studies with full-length fibrinogen rather than the γ-
module. For these experiments, we will introduce chemical crosslinks between FXIII and 
fibrinogen, which will link the binding domains together. By then utilizing protein cleavage, 
SDS-PAGE, Western blotting, and mass spectrometry, we will analyze the cleavage products for 
a fragment containing peptides from both FXIII and fibrinogen.14 We hypothesize that the 
cleavage fragment containing both FXIII and fibrinogen residues will contain the respective 
binding domains for each protein. Better understanding of the FXIII-fibrinogen interaction may 
provide targets for new anti-thrombotic therapies. 
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Figure 1. Forward and reverse primers used in γ-module PCR. The forward primer 
contained restriction enzyme sites for BamHI and NdeI, and the reverse primer contained a 
restriction enzyme site for HindIII. 
 
Figure 2. FXIII-A2B2 shows reduced affinity for γ-mod390-396A compared to γ-modNat. FXIII-
γ-module binding was measured by ELISA. Briefly, microplates were coated with 10 μg/mL 
FXIII-A2B2 and blocked with HBS plus Ca
2+ plus 1% bovine serum albumin. γ-modNat and 390-
396A were added to the wells, and binding was detected with a peroxidase-conjugated anti-
fibrinogen antibody and peroxidase substrate. Data are means ± standard error of n = 3 
experiments. 
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Figure 3. FXIII-mediated crosslinking of γ-modNat and γ-mod390-396A. Crosslinking of γ-
module by recombinant(r)-FXIII-A2 (A, B) or FXIII-A2B2 (C, D) was measured by incubating γ-
modNat (A, C) or γ-mod390-396A (B, D) with FXIII in the presence of thrombin (5 nM) and CaCl2 
(5 mM). Timed samples were analyzed by SDS-PAGE and Western blotting with anti-human 
fibrinogen antibody. Control lanes marked as γ-modNat or γ-mod390-396A contain only γ-module 
without FXIII and thrombin. 
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Figure 4. FXIII-A subunit activation during crosslinking. Activation rates of r-FXIII-A2 (A, 
B) and FXIII-A2B2 (C, D) during crosslinking were measured by incubating γ-modNat (A, C) or 
γ-mod390-396A (B, D) with FXIII in the presence of thrombin (5 nM) and CaCl2 (5 mM). FXIII 
activation was detected by re-probing membranes from crosslinking reactions with an anti-
human FXIII-A antibody. FXIII activation corresponds with a molecular weight shift following 
activation peptide cleavage. Control lanes marked as γ-modNat or γ-mod390-396A contain only γ-
module without FXIII and thrombin. 
 
Figure 5. Solution-phase activation of FXIII-A2B2 and r-FXIII-A2. Solution-phase activation 
rates of r-FXIII-A2 (A) and FXIII-A2B2 (B) were measured by incubating FXIII in the presence 
of thrombin (5 nM) and CaCl2 (5 mM). Timed samples were quenched and analyzed by SDS-
PAGE and Western blotting with anti-human FXIII-A antibody. Control lanes marked FXIII-
A2B2 and r-FXIII-A2 contained the indicated FXIII and lacked thrombin. 
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Figure 6. Tethered cleavage chemistry of γ-modG397C. In the “Reaction” lanes, γ-modG397C was 
treated with FeBABE reagent and subsequently incubated with FXIII-A2B2. “High Reaction” 
contained a higher concentration of γ-modG397C compared to the “Low Reaction”. “Reactions” 
and lanes termed “+ trigger” received the ascorbic acid and hydrogen peroxide trigger and were 
reacted for 30 seconds before being quenched with sample buffer. Controls contained γ-modG397C 
alone, FXIII alone, FXIII plus trigger, γ-modG397C plus FXIII plus trigger, and FeBABE-γ-
modG397C conjugate plus FXIII (not triggered). Samples were analyzed by SDS-PAGE and 
Western blotting with anti-human FXIII-A antibody. Reaction lanes displayed unique cleavage 
fragments at approximately 27, 35, 38, 45, 50, and 57 kDa (A). The presence of these same 
bands in the FXIII-FeBABE control lane (B) suggests that these fragments result from direct 
conjugation of FeBABE to free cysteines on FXIII-A in the “Reactions”. 
 
